Xencor, Inc. (XNCR) News

Xencor, Inc. (XNCR): $31.17

-0.62 (-1.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XNCR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 498

in industry

Filter XNCR News Items

XNCR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XNCR News Highlights

  • 500 - Internal server error
  • Over the past 28 days, the trend for XNCR's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about XNCR are JAZZ and SVRA.

Latest XNCR News From Around the Web

Below are the latest news stories about Xencor Inc that investors may wish to consider to help them evaluate XNCR as an investment opportunity.

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

MONROVIA, Calif., July 28, 2021--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021.

Yahoo | July 28, 2021

Were Hedge Funds Right About Xencor Inc (XNCR)?

In this article we will take a look at whether hedge funds think Xencor Inc (NASDAQ:XNCR) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]

Yahoo | July 27, 2021

Xencor (XNCR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 27, 2021

Down 10.9% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | July 27, 2021

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

Yahoo | July 1, 2021

Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze

Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

Yahoo | July 1, 2021

Xencor (XNCR) Loses 12.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | June 30, 2021

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Yahoo | June 22, 2021

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

Purchase of Xencor Option potentially eliminates approximately 2.1 mill ion shares of INmune future common stock dilution upon execution.

Intrado Digital Media | June 14, 2021

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

Omeros (OMER) announces initial results from a phase I study of OMS906.

Yahoo | June 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6054 seconds.